Lonza Group Ltd. (Basel, Switzerland, www.lonza.com) and Bio*One Capital (Centros, Singapore, www.bio1capital.com) have signed a joint venture - Lonza Biologics Tuas - to build a large-scale mammalian cell culture facility in Singapore for the manufacture of commercial biopharmaceuticals.
Lonza Group Ltd. (Basel, Switzerland, www.lonza.com) and Bio*One Capital (Centros, Singapore, www.bio1capital.com) have signed a joint venture - Lonza Biologics Tuas - to build a large-scale mammalian cell culture facility in Singapore for the manufacture of commercial biopharmaceuticals. The facility will be Lonza’s second large-scale mammalian manufacturing plant in Singapore, and the third one globally. The capital investment will amount up to $350 million.
Lonza Biologics Tuas, located in Tuas Biomedical Park, will have up to four mammalian bioreactor trains, each with a flexible capacity of 1,000 L up to 20,000 L. The facility will become operational in 2011. When fully completed, Lonza Biologics Tuas expects to hire approximately 350 people for the operation.
In February 2006 Lonza and Bio*Capital entered into an initial joint venture under the name Lonza Biologics Singapore Pte Ltd., to build an 80,000 liter large-scale mammalian biopharmaceutical production facility. This facility became 100% owned by Lonza upon the signing of the Lonza Biologics Tuas joint venture. Genentech has an exclusive option to acquire the Lonza owned facility between 2007 and 2012.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.